About AcelRx Pharmaceuticals (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500
Debt
Debt-to-Equity Ratio-0.31%
Current Ratio4.64%
Quick Ratio4.57%
Price-To-Earnings
Trailing P/E Ratio-2.20
Forward P/E Ratio-2.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.99 million
Price / Sales15.03
Cash FlowN/A
Price / CashN/A
Book Value($0.73) per share
Price / Book-3.23
Profitability
EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-644.25%
Return on EquityN/A
Return on Assets-63.41%
Miscellaneous
Employees41
Outstanding Shares50,900,000
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, March, 8th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). The specialty pharmaceutical company earned $0.74 million during the quarter, compared to the consensus estimate of $2.90 million. View AcelRx Pharmaceuticals' Earnings History.
What price target have analysts set for ACRX?
7 brokerages have issued 12-month price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $5.40 in the next year. View Analyst Ratings for AcelRx Pharmaceuticals.
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include Viking Therapeutics (VKTX), Ardelyx (ARDX), Ovid Therapeutics (OVID), Aratana Therapeutics (PETX), Ocular Therapeutix (OCUL), Synlogic (SYBX), Corvus Pharmaceuticals (CRVS), Verona Pharma plc - American Depositary Share (VRNA), Evolus (EOLS), Fortress Biotech (FBIO), Recro Pharma (REPH), Melinta Therapeutics (MLNT), Calithera Biosciences (CALA), MannKind (MNKD), VBI Vaccines (VBIV), CTI BioPharma (CTIC), Tyme Technologies (TYME) and Tocagen (TOCA).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder, Chief Medical Officer and Director (Age 55)
- Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
- Mr. Vincent J. Angotti, CEO & Director (Age 50)
Has AcelRx Pharmaceuticals been receiving favorable news coverage?
Media coverage about ACRX stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a news impact score of 0.04 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.65 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $2.36.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $122.16 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)
| Community Ranking: | | 2.9 out of 5 ( ) |
| Outperform Votes: | | 285 (Thanks for Voting!) |
| Underperform Votes: | | 211 (Thanks for Voting!) |
| Total Votes: | | 496 |
AcelRx Pharmaceuticals (NASDAQ:ACRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for AcelRx Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 128.81%. The high price target for ACRX is $8.00 and the low price target for ACRX is $2.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.57 | 2.57 | 2.57 | 2.57 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.40 | $5.40 | $6.8333 | $7.6667 |
| Price Target Upside: | 128.81% upside | 200.00% upside | 279.63% upside | 260.78% upside |
AcelRx Pharmaceuticals (NASDAQ:ACRX) Consensus Price Target History
AcelRx Pharmaceuticals (NASDAQ:ACRX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
AcelRx Pharmaceuticals (NASDAQ:ACRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 9.20%
AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/14/2017 | Mark G Edwards | Director | Buy | 30,000 | $1.90 | $57,000.00 | 150,000 |  |
| 11/13/2017 | Raffi Asadorian | CFO | Buy | 5,000 | $1.94 | $9,700.00 | 12,000 | |
| 10/2/2017 | Lawrence G Hamel | Insider | Sell | 10,161 | $5.29 | $53,751.69 | 16,379 | |
| 9/11/2017 | Raffi Asadorian | CFO | Buy | 7,000 | $3.24 | $22,680.00 | 7,000 | |
| 8/24/2017 | Mark G Edwards | Director | Buy | 5,000 | $3.02 | $15,100.00 | 115,200 | |
| 8/24/2017 | Vincent J Angotti | CEO | Buy | 15,000 | $3.00 | $45,000.00 | 15,000 | |
| 8/22/2017 | Pamela P. Palmer | Insider | Buy | 10,000 | $2.95 | $29,500.00 | | |
| 6/19/2017 | Life Sciences Maste Perceptive | Major Shareholder | Sell | 875,000 | $2.40 | $2,100,000.00 | | |
| 9/29/2016 | Perceptive Advisors Llc | Major Shareholder | Sell | 216,500 | $3.92 | $848,680.00 | | |
| 9/15/2016 | Perceptive Advisors Llc | Major Shareholder | Sell | 392,850 | $3.70 | $1,453,545.00 | | |
| 5/13/2016 | Howard B Rosen | CEO | Buy | 10,206 | $3.26 | $33,271.56 | 50,000 | |
| 5/12/2016 | Mark G Edwards | Director | Buy | 15,000 | $3.15 | $47,250.00 | 105,000 | |
| 11/18/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 176,200 | $5.35 | $942,670.00 | | |
| 11/6/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 92,100 | $4.59 | $422,739.00 | | |
| 9/9/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 310,000 | $4.18 | $1,295,800.00 | | |
| 5/7/2015 | Mark G Edwards | Director | Buy | 40,000 | $3.13 | $125,200.00 | | |
| 3/10/2014 | Mark Wan | Director | Sell | 1,000,000 | $12.35 | $12,350,000.00 | | |
| 11/7/2013 | Perceptive Advisors Llc | major shareholder | Buy | 200,000 | $6.51 | $1,302,000.00 | | |
| 11/4/2013 | Perceptive Advisors Llc | major shareholder | Buy | 155,000 | $6.87 | $1,064,850.00 | | |
| 11/1/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 360,660 | $6.91 | $2,492,160.60 | | |
| 9/20/2013 | Guy Nohra | Director | Sell | 158,153 | $10.59 | $1,674,840.27 | | |
| 9/18/2013 | Guy Nohra | Director | Sell | 128,780 | $10.42 | $1,341,887.60 | | |
| 7/23/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 850,000 | $11.65 | $9,902,500.00 | | |
| 6/6/2013 | Mark G Edwards | Director | Buy | 10,000 | $8.10 | $81,000.00 | | |
| 5/28/2013 | Adrian Adams | Director | Buy | 75,000 | $8.19 | $614,250.00 | | |
| 12/7/2012 | Mark A Wan | Director | Buy | 2,416,918 | $3.31 | $7,999,998.58 | | |
(Data available from 1/1/2013 forward)
AcelRx Pharmaceuticals (NASDAQ ACRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM |
| -$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 18 at 8:32 AM |
 | Pharmacokinetics of AcelRx Pharma's sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarket
seekingalpha.com - April 18 at 8:16 AM |
 | AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
finance.yahoo.com - April 18 at 8:16 AM |
| Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
finance.yahoo.com - April 18 at 8:16 AM |
| AcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM |
| AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2
seekingalpha.com - April 16 at 8:15 AM |
| AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
finance.yahoo.com - April 16 at 8:15 AM |
| AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM |
| AcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 14 at 11:48 AM |
| AcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - April 12 at 12:29 AM |
| AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 5:43 PM |
| AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
finance.yahoo.com - April 11 at 5:32 PM |
| AcelRx Pharmaceuticals (ACRX) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 8 at 7:34 PM |
 | PDL BioPharma to Present at the HC Wainwright Global Life Sciences Conference
www.prnewswire.com - April 3 at 5:35 PM |
| AcelRx Pharmaceuticals (ACRX) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - April 1 at 7:23 AM |
| AcelRx announces appointment of John Saia as General Counsel
finance.yahoo.com - March 27 at 8:27 AM |
| When Can We Expect A Profit From AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?
finance.yahoo.com - March 21 at 8:47 AM |
| Technical Perspectives on Medical Equipment Stocks -- Accuray, AcelRx Pharma, Aethlon Medical, and CHF Solutions - PR Newswire (press release)
www.prnewswire.com - March 20 at 8:27 AM |
| Edited Transcript of ACRX earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:16 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM |
| Analysts Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $780,000.00
www.americanbankingnews.com - March 17 at 8:38 AM |
| Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) to Announce -$0.24 EPS
www.americanbankingnews.com - March 15 at 3:10 AM |
| AcelRx Pharmaceuticals Inc (ACRX) to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 12 at 2:50 AM |
 | Pre-Open Movers 03/09: (PDLI) (ACRX) (ECYT) Higher; (AUTO) (VNRX) (BIG) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 10 at 8:21 AM |
| After-Hours Stock Movers 03/08: (PDLI) (ACRX) (UNFI) Higher; (AUTO) (VNRX) (FNSR) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 9 at 8:19 AM |
 | FDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month - Nasdaq
www.nasdaq.com - March 9 at 8:19 AM |
 | 26 Stocks Moving In Friday's Pre-Market Session - Benzinga
www.benzinga.com - March 9 at 8:19 AM |
| AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:19 AM |
| AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 8 at 6:45 PM |
| AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018
finance.yahoo.com - March 8 at 6:45 PM |
| Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
finance.yahoo.com - March 7 at 6:35 PM |
| AcelRx Pharmaceuticals to Participate at Three Upcoming Investor ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:17 AM |
| AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March
finance.yahoo.com - March 5 at 8:17 AM |
| Analyzing Stemline Therapeutics (STML) and AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - March 2 at 1:39 PM |
| AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 8:15 AM |
| AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results Conference Call and Webcast on Thursday, March 8th, 2018
finance.yahoo.com - March 2 at 8:15 AM |
| Brokerages Expect AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million
www.americanbankingnews.com - February 28 at 11:36 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 20 at 5:32 PM |
| AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 16 at 8:17 AM |
| Jefferies Group Weighs in on AcelRx Pharmaceuticals Inc's FY2019 Earnings (ACRX)
www.americanbankingnews.com - February 15 at 3:10 PM |
| Brokers Offer Predictions for AcelRx Pharmaceuticals Inc's FY2022 Earnings (ACRX)
www.americanbankingnews.com - February 14 at 4:14 PM |
| AcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 26 at 5:38 PM |
| Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 25 at 3:44 AM |
| AcelRx Pharmaceuticals (ACRX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 5:28 PM |
| AcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 16 at 5:24 PM |
| Zacks Investment Research Downgrades AcelRx Pharmaceuticals (ACRX) to Hold
www.americanbankingnews.com - January 15 at 4:28 PM |
| Zacks: Brokerages Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 8 at 4:40 PM |
| Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - January 6 at 11:28 AM |
| How to Short a Stock - Benzinga
www.benzinga.com - January 4 at 5:20 AM |
AcelRx Pharmaceuticals (NASDAQ:ACRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AcelRx Pharmaceuticals (NASDAQ:ACRX) Income Statement, Balance Sheet and Cash Flow Statement
AcelRx Pharmaceuticals (NASDAQ ACRX) Stock Chart for Friday, April, 20, 2018
Loading chart…
